Drugs / SG2918
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06167486 | Dec 2023 → Nov 2025 overdue | cancer | Hangzhou Sumgen Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07454187 | Apr 2026 → Sep 2027 expected | refractory plasma cell neoplasm | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-22 | Hangzhou Sumgen Biotech Co., Ltd. | Regulatory 尚健生物全球领先同靶点ADC药物SG2918获国家药品监督管理局批准临床试验 sumgenbio.com ↗
2023年10月20日，杭州尚健生物技术有限公司（以下简称“尚健生物”）宣布，其自主研发的创新ADC药物注射用SG2918临床试验申请获国家药品监督管理局（NMPA）批准，适应症为晚期恶性肿瘤。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-22 | Hangzhou Sumgen Biotech Co., Ltd. | 尚健生物全球领先同靶点ADC药物SG2918获国家药品监督管理局批准临床试验 sumgenbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SG2918 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06167486 ↗ |
| Route | Intravenous | “administrated by intravenous infusion” NCT06167486 ↗ |